Development and validation of RSClin N plus tool for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer

被引：0
|
作者：
Pusztai, Lajos
Hoag, Jess R.
Albain, Kathy S.
Barlow, William E.
Stemmer, Salomon M.
Meisner, Allison
Hortobagyi, Gabriel N.
Shak, Steven
Hayes, Daniel F.
Rae, James M.
Baehner, Frederick
Sharma, Priyanka
Kalinsky, Kevin
机构：
[1] Yale Univ, Canc Ctr, New Haven, CT USA
[2] Exact Sci, Redwood City, CA USA
[3] Loyola Univ, Chicago Stritch Sch Med, Cardinal Bernardin Canc Ctr, Maywood, IL USA
[4] Canc Res & Biostat CRAB, Seattle, WA USA
[5] Rabin Med Ctr, Petah Tiqwa, Israel
[6] Fred Hutchinson Canc Ctr, Div Publ Hlth Sci, Seattle, WA USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX USA
[8] Univ Michigan Hlth Syst, Comprehens Canc Ctr, Ann Arbor, MI USA
[9] Michigan Med, Ann Arbor, MI USA
[10] Univ Kansas, Canc Ctr, Westwood, KS USA
[11] Emory Univ, Winship Canc Inst, Atlanta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
508
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
    Ditsch, Nina
    Schmidt, Marcus
    [J]. GEBURTSHILFE UND FRAUENHEILKUNDE, 2019, 79 (12) : 1328 - 1335
  • [2] First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC)
    Hortobagyi, G. N.
    Stemmer, S. M.
    Burris, H. A.
    Yap, Y. S.
    Sonke, G. S.
    Paluch-Shimon, S.
    Campone, M.
    Blackwell, K.
    Andre, F.
    Winer, E. P.
    Janni, W.
    Verma, S.
    Conte, P.
    Arteaga, C. L.
    Cameron, D.
    Xuan, F.
    Souami, F.
    Miller, M.
    Germa, C.
    O'Shaughnessy, J.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [3] Ribociclib (RIB) plus endocrine therapy (ET) in Japanese women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC)
    Masuda, N.
    Noguchi, S.
    Ishikawa, T.
    Aruga, T.
    Kim, S. J.
    Toyama, T.
    Saeki, T.
    Saito, M.
    Yamanaka, T.
    Watanabe, J.
    Nakamura, S.
    Takahashi, M.
    Inoue, K.
    Gounaris, I.
    Han, Y.
    Samant, T. S.
    Gazdoiu, M.
    Ito, Y.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [4] Surgical Management of the Axilla in Patients Presenting with Clinically Node Positive Hormone Receptor Positive, HER2 Negative (HR+/HER2-) Breast Cancer
    Jasper, Jacob
    Kantor, Olga
    Dorninici, Laura
    Nakhlis, Faina
    Ogayo, Esther
    Nimbkar, Suniti
    Kurt, Busem Binbogct
    King, Tari
    Mittendorf, Elizabeth
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S101 - S101
  • [5] The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value?
    Aapro, Matti
    De Laurentiis, Michelino
    Rea, Dan
    Bargallo Rocha, Juan Enrique
    Elizalde, Roberto
    Landherr, Laszlo
    Linderholm, Barbro
    Mamounas, Eleftherios
    Markopoulos, Christos
    Neven, Patrick
    Petrovsky, Alexander
    Rouzier, Roman
    Smit, Vincent
    Svedman, Christer
    Schneider, Daniel
    Thomssen, Christoph
    Martin, Miguel
    [J]. BREAST, 2017, 33 : 191 - 199
  • [6] The clinical impact of NOLUS in unresectable/metastatic hormone receptor-positive (HR+)/HER2-negative breast cancer
    Tajiri, Wakako
    Nakamura, Yoshiaki
    Kawasaki, Junji
    Koi, Yumiko
    Akiyoshi, Sayuri
    Koga, Chinami
    Tokunaga, Eriko
    [J]. CANCER RESEARCH, 2024, 84 (09)
  • [7] Ribociclib plus letrozole vs placebo plus letrozole in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) and a high disease burden
    Verma, S.
    Gil-Gil, M.
    Hegg, R.
    Wheatley-Price, P.
    Kattan, J.
    Bourgeois, H.
    Sutradhar, S.
    Miller, M.
    Campone, M.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [8] Biomarker analyses of Asian women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) receiving ribociclib (RIB) plus endocrine therapy (ET)
    Yap, Y. S.
    Masuda, N.
    Ito, Y.
    Ishikawa, T.
    Kim, S. J.
    Aruga, T.
    Toyama, T.
    Saeki, T.
    Yamanaka, T.
    Saito, M.
    Watanabe, J.
    Takahashi, M.
    Nakamura, S.
    Inoue, K.
    Suarez-Vizcarra, J.
    He, W.
    Solovieff, N.
    Su, F.
    Chiu, J.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 13 - +
  • [9] Bosutinib and exemestane (EXE) versus EXE alone in postmenopausal (postm) women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (ABC).
    Moy, B.
    Lebrun, F.
    Bellet, M.
    Chow, L.
    Lang, I.
    Xu, B.
    Badwe, R. A.
    Hershman, D. L.
    Leip, E.
    Bardy-Bouxin, N.
    Duvillie, L.
    Neven, P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
    Cantini, Luca
    Trapani, Dario
    Guidi, Lorenzo
    Bielo, Luca Boscolo
    Scafetta, Roberta
    Koziej, Marcin
    Vidal, Laura
    Saini, Kamal S.
    Curigliano, Giuseppe
    [J]. CANCER TREATMENT REVIEWS, 2024, 123
12345